Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

Rahul Aggarwal, Charles J. Ryan, June M. Chan

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations

Abstract

Androgen deprivation therapy (ADT) is standard of care for patients with metastatic hormone-sensitive prostate cancer (HSPC), yet through its induction of a hypogonadal state leads to metabolic perturbations, including insulin resistance (IR) and obesity. IR and obesity have been associated with an increased risk of progression to castrate-resistant prostate cancer (CRPC) and ultimately increased prostate cancer-specific mortality. On a molecular level, this association between obesity/IR and prostate cancer progression may be mediated by alterations in the insulin-like growth factor (IGF) axis, which has been shown to be up-regulated upon disease progression to CRPC. Targeting the IGF axis, either by anti-IGF therapy or via enhancement of peripheral insulin sensitivity, represents a viable therapeutic target in patients with prostate cancer. Using the development of IR and/or obesity may represent a clinically available biomarker that may predict those patients most likely to respond to such therapy, and warrants testing in future prospective clinical trials.

Original languageEnglish (US)
Pages (from-to)522-530
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Volume31
Issue number5
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Keywords

  • Androgen deprivation therapy
  • Castration-resistant
  • Insulin resistance
  • Insulin-like growth factor
  • Prostate cancer

Fingerprint

Dive into the research topics of 'Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?'. Together they form a unique fingerprint.

Cite this